SpinalCyte announced issuance of U.S. Patent No. 10,052,410, “Methods and Compositions For Repair Of Cartilage Using An In Vivo Bioreactor.”
The technology described in the patent involves an in vivo bioreactor which acts as a delivery system to feed and grow cells, like fibroblasts, and induces cellular differentiation. Additionally, the device will also be subject to one or more growth factors which may enhance differentiation of the cells.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
“Our patent portfolio uniquely positions us at the forefront of human dermal fibroblast cell therapy for spinal disc regeneration,” said Pete O’Heeron, Chief Executive Officer, SpinalCyte. “As leaders in this field, we continue to expand our intellectual property protections.”
With this addition, SpinalCyte’s portfolio now includes 33 U.S. and foreign patents issued and 43 patents pending.